NYSE · traded in Congress
Boston Scientific BSX
$42.01 +0.03 (+0.07%) Nov 2, 2026 4:25 AM ET
Market value$60.9B
P/E ratio-
Analyst target$50.00
52-week range-
Avg volume8,684,835
Dividend yield-
Chart
Analyst ratings
- 23 buy
- 10 hold
- 0 sell
Low target$41.00
Average target$50.48
High target$67.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $5,138M | $3,428M | - | - | |
| $5,442M | $3,848M | - | - | |
| $5,203M | $3,614M | - | - | |
| $5,285M | $3,678M | - | - |
New SEC filings
- 4 4 filed Nov 6, 2026
- SCHEDULE 13G/A SCHEDULE 13G/A filed Nov 6, 2026
All BSX filings on SEC EDGAR ›
Congress trades in BSX
Members of Congress disclosed 13 transactions in BSX in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 09/09/2026 | Kevin Hern OK01 | Sale | $50,001 - $100,000 | 9/25/2026 filing |
| 09/04/2026 | Kevin Hern OK01 | Partial sale | $50,001 - $100,000 | 9/25/2026 filing |
| 09/03/2026 | Kevin Hern OK01 | Sale | $1,001 - $15,000 | 9/25/2026 filing |
| 09/03/2026 | Kevin Hern OK01 | Sale | $1,001 - $15,000 | 9/25/2026 filing |
| 09/03/2026 | Kevin Hern OK01 | Sale | $1,001 - $15,000 | 9/25/2026 filing |
| 08/31/2026 | Kevin Hern OK01 | Sale | $15,001 - $50,000 | 9/25/2026 filing |
| 08/18/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 9/10/2026 filing |
| 06/05/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 7/2/2026 filing |
| 06/05/2026 | Gilbert Cisneros CA31 | Partial sale | $1,001 - $15,000 | 7/2/2026 filing |
| 05/29/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 05/19/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 05/11/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 02/10/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 3/9/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
